Antonelli Financial Advisors LLC bought a new position in Stryker Co. (NYSE:SYK – Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 2,147 shares of the medical technology company’s stock, valued at approximately $773,000. Stryker accounts for approximately 0.7% of Antonelli Financial Advisors LLC’s investment portfolio, making the stock its 24th biggest holding.
Several other hedge funds have also added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker in the 4th quarter worth $25,000. Dunhill Financial LLC boosted its holdings in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the period. Rakuten Securities Inc. grew its stake in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in Stryker during the 4th quarter valued at about $30,000. Finally, BankPlus Trust Department bought a new position in Stryker during the 4th quarter valued at approximately $33,000. 77.09% of the stock is owned by institutional investors.
Insider Activity
In related news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on Stryker
Stryker Stock Performance
Shares of SYK stock opened at $373.69 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company has a market capitalization of $142.59 billion, a price-to-earnings ratio of 48.16, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company’s 50-day moving average is $384.18 and its 200 day moving average is $373.85.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 earnings per share. Sell-side analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.
Stryker Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.90%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.
Stryker Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Recommended Stories
- Five stocks we like better than Stryker
- Profitably Trade Stocks at 52-Week Highs
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Golden Cross Stocks: Pattern, Examples and Charts
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Investing in Travel Stocks Benefits
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.